Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Self-reported manifestations of topical steroid withdrawal in atopic dermatitis include erythema, desquamation, dryness, and oozing.

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting ... across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard.

Based on these findings, you diagnose his skin disease as atopic dermatitis (AD). AD is a common, genetic, recurring, inflammatory, pruritic skin disease, which usually develops during infancy or ...

The Food and Drug Administration (FDA) has approved the biologic drug dupilumab (Dupixent). Doctors prescribe it for people with moderate to severe atopic dermatitis when topical treatments do not ...

Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...